Fusion

Fusion Fuel Announces Award of €3.3 Million H2 Pioneros Grant for 2.4 MW Green Hydrogen Project in Spain

Retrieved on: 
Tuesday, February 28, 2023
Transformation, Pioneros de Cancún, Economic recovery, Renewable energy, Fusion

SABUGO, Portugal, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Fusion Fuel (NASDAQ: HTOO) is pleased to announce that, Fusion Fuel Spain, has been awarded a grant of €3.3 million towards capital investment in a 2.4 MW green hydrogen project aimed at industrial decarbonization in Spain.

Key Points: 
  • SABUGO, Portugal, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Fusion Fuel (NASDAQ: HTOO) is pleased to announce that, Fusion Fuel Spain, has been awarded a grant of €3.3 million towards capital investment in a 2.4 MW green hydrogen project aimed at industrial decarbonization in Spain.
  • The grant has been awarded through the H2 Pioneros Program, to which €150 million had been earmarked to support commercial projects across the renewable hydrogen value chain.
  • Fusion Fuel’s project is one of only 19 across Spain that were awarded grant financing through H2 Pioneros.
  • Our project in Toledo now joins an ever-growing list of green hydrogen projects in Spain.

Axiom Exhibiting at Outsourcing in Clinical Trials West Coast 2023

Retrieved on: 
Tuesday, February 28, 2023
Data analysis, Privacy, Metric, Trial of the century, Innovation, Suite, Attention, Fusion, Booth, Axiom, Clinical data management, Coffee, Engagement, Pharmaceutical industry, Online shopping, Maliha

TORONTO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at Outsourcing in Clinical Trials West Coast 2023, March 1-2 in Burlingame, CA.

Key Points: 
  • TORONTO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at Outsourcing in Clinical Trials West Coast 2023, March 1-2 in Burlingame, CA.
  • The 15th annual conference will provide experts in the life science industry to connect and explore solutions to current operational and outsourcing challenges associated with clinical trials.
  • Established in 2001, Axiom developed and has long been established as one of the leading global players and delivery experts in eClinical technology.
  • Axiom Fusion eClinical Suite enables small to medium life science companies to dramatically change how you manage US and global clinical studies.

Fusion Medical Staffing Certified as 2023 Great Place to Work

Retrieved on: 
Monday, February 27, 2023
Great Places, Flower, Certification, System, Fusion, Management

OMAHA, Neb., Feb. 27, 2023 /PRNewswire/ -- For the second consecutive year, Fusion has been recognized as a Certified™ Great Place to Work®.

Key Points: 
  • OMAHA, Neb., Feb. 27, 2023 /PRNewswire/ -- For the second consecutive year, Fusion has been recognized as a Certified™ Great Place to Work®.
  • This year, 93% of employees said Fusion is a great place to work – 36% higher than the average U.S. company.
  • Great Place to Work® is the global authority on workplace culture, employee experience, and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation.
  • Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience.

AUTODESK, INC. ANNOUNCES FISCAL 2023 FOURTH QUARTER AND FULL-YEAR RESULTS

Retrieved on: 
Thursday, February 23, 2023
Cloud, Spend, RPO, Balance sheet, Eric, Assemble, Intelligence, Tax, ShotGrid, Workflow, Public expenditure, Autodesk Revit, AutoCAD, Maintenance, Cyprus Securities and Exchange Commission, GAAP, Software, Privacy, Acquisition, Investment, National Entertainment Collectibles Association, ASC, Revenue, Legislation, Collection, Cloud computing, Act, Tax Cuts and Jobs Act of 2017, Intellectual property, Form 10-K, Fusion, Fusion 360, Autodesk 3ds Max, Health, USD, Creative, Cryptocurrency, Real estate, Video game, Life insurance, Bank, Music, Engineering, Design, Autodesk

The first quarter and full-year fiscal 2024 outlook assume a projected annual effective tax rate of 24 percent for GAAP and 18 percent for non-GAAP results, respectively.

Key Points: 
  • The first quarter and full-year fiscal 2024 outlook assume a projected annual effective tax rate of 24 percent for GAAP and 18 percent for non-GAAP results, respectively.
  • As such, assumptions for the annual effective tax rate are evaluated regularly and may change based on the projected geographic mix of earnings.
  • Autodesk will host its fourth quarter conference call today at 5 p.m.
  • For certain cloud service offerings and EBAs, subscriptions represent the monthly average activity reported within the last three months of the fiscal quarter end date.

Announcing Innovative New Tech Industry Event Channel Fusion Expo, Taking Place June 7-9 in Charlotte, NC

Retrieved on: 
Thursday, February 16, 2023
Cloud, Satellite navigation, Charlotte Convention Center, Meeting, VARS, Fusion, Convention, Channel, Member of the Scottish Parliament, Marketing, Partnership, Incentive, TSB Bank Arena, MCI, Sales

“Channel Fusion represents a much-needed change in how technology events are delivered by creating a new and unique journey for technology sellers and their providers,” says Carolyn Bradfield, CEO & Founder of Convey.

Key Points: 
  • “Channel Fusion represents a much-needed change in how technology events are delivered by creating a new and unique journey for technology sellers and their providers,” says Carolyn Bradfield, CEO & Founder of Convey.
  • “Cloud Conventions provided an enhanced virtual experience, superior content, and extended engagement during the height of the pandemic.
  • Attendees can make purposeful connections, generate ideas, and explore real-world strategies in a collaborative environment comprising over forty educational sessions and leading exhibitors.
  • View schedule, topics, and register (registration for workshops includes a discount off tickets to the live event).

RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharmaceuticals Inc.

Retrieved on: 
Wednesday, February 15, 2023
Medical director, TAT, Catastrophic illness, National Cancer Institute, Patient, Safety, Acquisition, Clinical trial, Prostate cancer, American Cancer Society, Prevalence, Radiopharmaceutical, World Health Organization, Death, IND, Pharmaceutical industry, Fusion

Houston, TX, Feb. 15, 2023 (GLOBE NEWSWIRE) -- RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage radiopharmaceutical company announced the acquisition of it’s 225Ac-PSMA-I&T asset by Fusion Pharmaceuticals.

Key Points: 
  • Houston, TX, Feb. 15, 2023 (GLOBE NEWSWIRE) -- RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage radiopharmaceutical company announced the acquisition of it’s 225Ac-PSMA-I&T asset by Fusion Pharmaceuticals.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • 225Ac-PSMA-I&T is currently being evaluated under a phase 2 physician-sponsored investigational new drug (IND) under the acronym of TATCIST trial.
  • Of these, approximately 10–20% of cases progress after androgen deprivation therapy to the more aggressive disease stage of metastatic castration resistant prostate cancer (mCRPC).

Arima Genomics and Velsera Announce Partnership to Enable Broad Adoption of Arima Gene Fusion Test in Clinical Laboratories

Retrieved on: 
Tuesday, February 7, 2023
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Software, Genetics, Science, Strategic management, Library, Laboratory, Genomics, Workflow, Fusion, CGW, NGS, Data analysis, RNA, Senior, Arima, Neoplasm, Vaccine, Pierian Spring

Under the terms of the agreement, Velsera will integrate Arima Genomics’ targeted next-generation sequencing (NGS) testing pipelines into the Pierian Clinical Genomics Workspace (CGW), the leading cloud-based platform that provides clinical labs more streamlined and accurate NGS data analysis, interpretation, and reporting.

Key Points: 
  • Under the terms of the agreement, Velsera will integrate Arima Genomics’ targeted next-generation sequencing (NGS) testing pipelines into the Pierian Clinical Genomics Workspace (CGW), the leading cloud-based platform that provides clinical labs more streamlined and accurate NGS data analysis, interpretation, and reporting.
  • The combined solution will enable clinical laboratories to more easily implement sample-to-answer Arima gene fusion testing, helping them identify gene fusions and other structural variants.
  • “Adopting new NGS technologies and instituting new protocols for clinical genomic interpretation and reporting is time-consuming and challenging,” said Chris Roberts, Senior Vice President, Corporate Strategy at Arima Genomics.
  • “We look forward to integrating Arima Genomics’ gene fusion detection technology into our Clinical Genomics Workspace platform.

Sigma7 Expands Advisory Board with Four New Appointments

Retrieved on: 
Tuesday, February 7, 2023
Consulting, Fintech, Professional Services, Business, Organization, GenOn Energy, Government, Transocean, Microsoft, NRG Energy, Government of the United Kingdom, Senior, Risk, Princeton University, Mining, GlobalSantaFe Corporation, Policy, Advisory board, Institute of Directors, Multimedia, Chair, Fusion, Defense, Management, Sigma Seven

In bolstering its Advisory Board of respected, world-class leaders from military, national security and industry backgrounds, the company expands its ability to help the world’s most critical organizations assess, mitigate and respond to risk.

Key Points: 
  • In bolstering its Advisory Board of respected, world-class leaders from military, national security and industry backgrounds, the company expands its ability to help the world’s most critical organizations assess, mitigate and respond to risk.
  • “We are honored to welcome four outstanding government and industry leaders to Sigma7’s Advisory Board.
  • Tom Cosentino, and Dr. Nadia Schadlow on Sigma7’s Advisory Board.
  • He has extensive mining executive and board experience and is a long-time Fellow of the Institute of Directors (UK).

Pre-download Now Available for ‘MIR M: Vanguard & Vagabond’!

Retrieved on: 
Tuesday, January 31, 2023
Data Management, Online, Mobile Entertainment, Technology, Finance, Apps, Applications, Blockchain, Professional Services, NFT, Electronic Games, Digital Cash Management, Digital Assets, Software, Entertainment, Internet, Mobile, Wireless, Attention, MMORPG, Freedom, DOGMA, Fusion, FIMO, IP, Mir, Multimedia, Apple, Exchange, MIR, Mobile phone

Wemade began the pre-download of its MMORPG MIR M: Vanguard & Vagabond (MIR M) on January 30, 2023.

Key Points: 
  • Wemade began the pre-download of its MMORPG MIR M: Vanguard & Vagabond (MIR M) on January 30, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230130005767/en/
    Wemade opens Pre-download for MIR M: Vanguard & Vagabond on January 30, and the official launch begins globally on January 31.
  • (Graphic: Wemade)
    Prior to its official release, MIR M can be downloaded from ‘Google Play’, ‘Apple App Store’ and its official website.
  • There are also plenty of events for MIR M users, where they can receive various summon tickets through daily check-in events and more.

Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

Retrieved on: 
Monday, February 13, 2023
Conference, Webcast, Pharmaceutical industry, Broadcasting, Fusion

HAMILTON, ON and BOSTON, Feb. 13, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023 at 12:00 p.m.

Key Points: 
  • HAMILTON, ON and BOSTON, Feb. 13, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023 at 12:00 p.m.
  • Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D, Chief Scientific Officer Christopher Leamon, Ph.D., and President and Chief Business Officer Mohit Rawat.
  • A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts .
  • A replay of the webcast will be archived on the Company's website for 90 days following their respective presentation dates.